North America Omega 3 Market: Emerging Trends in Functional Nutrition Products
Consumers are treating fish oil capsules and fortified foods
less like a luxury and more like routine preventive care, and manufacturers are
racing to keep pace. According to Polaris Market Research, the
North America Omega 3 Market was valued at USD 826.27 million in 2023
and is projected to reach USD 1,567.13 million by 2032, growing at a CAGR of
7.5%.
The Shift: What's Actually Changing in Omega 3 Demand
The change is behavioral as much as scientific. Chronic
conditions such as cardiovascular disorders, arthritis and cognitive decline
are pushing people toward proactive health measures, and EPA and DHA are among
the most studied nutrients for heart and brain health. For context, the CDC
reported roughly 695,000 heart disease deaths in the United States in 2021.
Rising costs reinforce the trend: according to the Centers for Medicare & Medicaid
Services, U.S. national health expenditure grew 4.1% to USD 4.5 trillion in
2022, nudging households to see supplements and functional foods as affordable
prevention. That is the engine behind current industry trends and sustained
market growth. Supportive regulatory frameworks and ongoing product innovation
add further momentum.
North America Omega 3 Market by the Numbers
With the market estimated at USD 875.65 million in 2024, the
trajectory looks like this:
- 2023
Market Size: USD 826.27 million
- 2032
Projected Size: USD 1,567.13 million
- CAGR
(2024–2032): 7.5%
👉 Want the full data
behind this shift? Get a Free Sample Report →
https://www.polarismarketresearch.com/industry-analysis/north-america-omega-3-market
Growth Drivers, Key Players and Market Segments to Watch
The expansion is being driven by rising healthcare
expenditure and growing consumer awareness — Natac's March 2025 launch of
Omega-3 Star, a fish oil solution for food, nutraceutical and pet nutrition,
shows the innovation pipeline at work — with key players including Aker
BioMarine, BASF SE, Croda International, and DSM-Firmenich shaping the
competitive landscape across segments such as By Type (DHA, ALA, EPA),
By Source (plant-based, marine-based), By Application, and By Country. As
healthcare costs take a bigger share of household budgets, people look for
convenient ways to manage their health before problems escalate, and omega-3s
have been studied for cardiovascular support, cognitive function and
inflammation reduction, which is why they increasingly sit inside a preventive
routine.
Segment and Competitive Highlights
Marine-based sources held the largest share in 2023, helped
by the region's abundant fish species, mature supply chains and the high EPA
and DHA concentrations that plant sources such as flaxseed or algal oil
struggle to match. By application, pharmaceuticals is expected to record the
fastest CAGR as prescription omega-3 products gain traction for conditions such
as elevated triglycerides. Buyers benchmarking top companies will also find GC
Rieber, Omega Protein, Corbion, Nuseed Global and Cargill in the report.
Marine-based products come as softgel capsules, liquid oils and fortified
foods, a breadth that suits diverse dietary needs, while functional food and
beverages, infant formula, dietary supplements and animal feed and pet food
complete the application picture.
Challenges That Could Slow Growth
Alternatives are the main headwind. Concerns about
sustainability, contaminants such as heavy metals, and the needs of vegetarian
and vegan consumers are steering some buyers toward algae-based omega-3, which
offers comparable benefits without the fish. As awareness of these alternatives
grows, demand for fish oil-derived products could soften, so suppliers with
both marine and plant-based portfolios may be better positioned.
The United States Leads Today, but Pharma-Grade Omega 3
Is Catching Up Fast
The United States accounted for more than 38% of the total
in 2023, a lead built on high disposable incomes, a strong wellness culture and
a healthcare system in which physicians, nutritionists and pharmacists
routinely recommend omega-3 products. The pharmaceutical segment, however, is
projected to post the highest CAGR through 2032 as clinical research keeps
supporting EPA and DHA formulations and drug developers invest in optimized
prescription versions. Canada rounds out the country coverage in the report.
What This Means for Teams Tracking the Omega 3 Market
Forecast 2032
For ingredient suppliers, supplement brands and investors
researching the North
America Omega 3 market forecast 2032, the underlying report breaks down
company positioning, segment-level forecasts, and regional opportunity through
2032 — useful context for any sourcing, partnership, or investment conversation
happening right now. The split between marine and plant-based sources, and
between dietary supplements and pharmaceutical-grade products, will shape where
margins and growth concentrate.
The Road Ahead
The next few years are likely to reward companies that
balance supply security with sustainability. Polaris anticipates strategic
collaborations, partnerships, mergers and acquisitions among leading players,
which should drive consolidation and product innovation. As algae-based options
mature and prescription formulations expand, an industry that began with a
simple health habit is becoming a broader ingredients-and-therapeutics
business. With consumers continuing to prioritize health and wellness, demand for
omega-3 fortified products is anticipated to remain robust, creating
opportunities for manufacturers and retailers.
More Trending Latest Reports By Polaris Market Research:
offshore-support-vessel-market
top-maleic-anhydride-manufacturers-and-key-insights-2024
top-10-electric-bike-sharing-services-companies-in-2025:-future-of-e-bikes-sharing
smart-home-energy-monitoring-devices-market
Comments
Post a Comment